🧵 Here are 10 amazing things that happened this year in #biotech.🧬
1. A HER2 targeting antibody-drug conjugate's stellar data redefined how breast cancer is categorized and offers a new treatment option for a large percentage of those with breast cancer in the future. fiercepharma.com/pharma/asco-as…
2. A GIP/GLP-1 receptor agonist helped patients lose as much as 22.5% of their body weight in a weight loss study, potentially addressing one of society's biggest health problems. nytimes.com/2022/04/28/hea…
3. A CD19 CAR-T was approved by FDA for second-line large B-cell lymphoma after going head-to-head against the decades-long standard of care, hematopoietic stem cell transplant, and beating it. fda.gov/drugs/resource…
4. A muscarinic agonist succeeded in a p3 trial for schizophrenia, potentially offering a new and better-tolerated mechanism of action for patients for the first time in decades. bostonglobe.com/2022/08/08/bus…
5. A medicine for ALS, a fixed-dose combo of sodium phenylbutyrate and taurursodiol, was granted approval by FDA, a win for patients who advocated for it. statnews.com/2022/09/29/fda…
6. An antibody that binds to amyloid-beta soluble protofibrils slowed cognitive decline in a p3 study of early Alzheimer's disease, finally. nytimes.com/2022/09/27/bus…
7. A thyroid hormone receptor (THR) β-selective agonist hit on both fibrosis and NASH resolution in a p3 study, potentially offering a treatment option for a lurking societal problem. endpts.com/madrigals-nash…
8. FDA approved two new CD3 bi-specifics for cancer. One targeting BCMA for multiple myeloma and the other CD20 for follicular lymphoma. An emerging modality goes mainstream. fiercepharma.com/pharma/roche-g…
9. An anti-TL1A monoclonal antibody notches a win for its class and produces arguably best-in-class efficacy and safety in IBD. biospace.com/article/promet…
10. A personalized mRNA cancer vaccine used in combo with Keytruda in the adjuvant setting for stage III/IV melanoma reduced the risk of recurrence or death by 44% vs Keytruda alone in a P2b study, potentially signaling a new era for cancer vaccines. wsj.com/articles/moder…
• • •
Missing some Tweet in this thread? You can try to
force a refresh
